Vir Biotechnology, Inc. 8-K

What Happened

• Vir Biotechnology, Inc. announced on June 9, 2026 that its Board increased from seven to eight members and appointed Timothy Coughlin, CPA, to fill the new seat as a Class III director. The appointment is effective immediately and Mr. Coughlin will serve until the Company’s 2028 annual meeting of stockholders. He was also appointed Chair of the Board’s Audit Committee.

Key Details

• Board change effective June 9, 2026: Board size increased from 7 to 8 members.
• Director class and term: Mr. Coughlin is a Class III director serving until the 2028 annual meeting.
• Committee role and background: Named Chair of the Audit Committee; Mr. Coughlin is a CPA.
• Compensation and agreements: As a non-employee director he will receive the Company’s standard cash and equity pay (per the non-employee director compensation policy described in Vir’s 2026 Proxy Statement). He received automatic stock option and restricted stock unit awards under the 2019 Equity Incentive Plan on his appointment date. The Company entered into its standard indemnity agreement with him. The filing states there are no related-party transactions between the Company and Mr. Coughlin requiring disclosure.

Why It Matters

• This changes Vir’s board composition and places a CPA in charge of the Audit Committee, which oversees financial reporting, internal controls and the relationship with external auditors — important areas for investor oversight.
• The appointment follows the Company’s standard director compensation and equity grant practices and the filing confirms no disclosed related-party issues. Investors should note the governance change and the term through the 2028 annual meeting when evaluating board continuity and oversight.